2025 APDD Summit

/in , , , , /by

2025 APDD Summit:

Sabirnetug overview and use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study, ALTITUDE-AD

2025 JPAD

/in , , , , , /by

2025 JPAD:

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer’s disease

2025 JPAD

/in , , , /by

2025 JPAD:

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

 

2024 CTAD Presentation

/in , , , , , , /by

2024 CTAD Presentation:

ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer’s Disease

2024 AAIC Poster

/in , , , , , , /by

2024 AAIC Poster:

Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 Study in Early AD

2024 AAIC Poster

/in , , , , , , /by

2024 AAIC Poster:

INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total Sabirnetug (ACU193) in Human CSF

2022 JPAD Article

/in , , , , /by

2022 Journal of Prevention of Alzheimer’s Disease:

 

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

2022 Frontiers in Neuroscience

/in , , , , /by

2022 Frontiers in Neuroscience:

 

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease